Neurolase targets a narrow, high-stakes moment in neurosurgery, real-time tumor margin identification, rather than a broader diagnostic or monitoring use case, using optical tissue chemistry read through AI rather than fluorescence dye or imaging. A first-in-human study across 30 patients and a Brain Tumour Charity accelerator grant give it early clinical traction, though funding so far is grant-based rather than institutional venture capital.